ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 142 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 4.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $39,000 | -15.2% | 2,085 | -46.9% | 0.00% | – |
Q2 2019 | $46,000 | -11.5% | 3,930 | -24.9% | 0.00% | – |
Q4 2018 | $52,000 | -40.2% | 5,234 | 0.0% | 0.00% | – |
Q3 2018 | $87,000 | +4.8% | 5,234 | 0.0% | 0.00% | – |
Q2 2018 | $83,000 | +23.9% | 5,234 | 0.0% | 0.00% | – |
Q1 2018 | $67,000 | +11.7% | 5,234 | 0.0% | 0.00% | – |
Q4 2017 | $60,000 | 0.0% | 5,234 | 0.0% | 0.00% | – |
Q3 2017 | $60,000 | 0.0% | 5,234 | 0.0% | 0.00% | – |
Q2 2017 | $60,000 | -44.4% | 5,234 | 0.0% | 0.00% | – |
Q1 2017 | $108,000 | -0.9% | 5,234 | 0.0% | 0.00% | – |
Q4 2016 | $109,000 | -68.1% | 5,234 | -50.0% | 0.00% | – |
Q3 2016 | $342,000 | +163.1% | 10,468 | +100.0% | 0.00% | – |
Q2 2016 | $130,000 | +97.0% | 5,234 | +93.9% | 0.00% | – |
Q1 2016 | $66,000 | -25.8% | 2,700 | 0.0% | 0.00% | – |
Q4 2015 | $89,000 | 0.0% | 2,700 | 0.0% | 0.00% | – |
Q3 2015 | $89,000 | -37.3% | 2,700 | 0.0% | 0.00% | – |
Q2 2015 | $142,000 | – | 2,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |